Mark A. Sidhom

Mark A. Sidhom

Auto-generated profile, based on publicly available information

Mark A. Sidhom

Peritoneal Malignancy Institute, Basingstoke North Hampshire Hospital Foundation Trust, Basingstoke, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
CSChristina Abdel Shaheed
Christina Abdel Shaheed
CHChristopher Hayes
Christopher Hayes
CMChristopher G. Maher
Christopher G. Maher
JBJane C. Ballantyne
Jane C. Ballantyne
MUMartin Underwood
Martin Underwood
MSMark A. Sidhom
Mark A. Sidhom
Pain is one of the most burdensome symptoms in people with cancer, and opioid analgesics are considered the mainstay of cancer pain management. For this review, the authors evaluated the efficacy and toxicities of opioid analgesics compared with placebo, other opioids, nonopioid analgesics, and nonpharmacologic treatments for background cancer pain (continuous and relatively constant pain present at rest), and breakthrough cancer pain (transient exacerbation of pain despite stable and adequately controlled background pain ). They found a paucity of placebo‐controlled trials for background cancer pain, although tapentadol or codeine may be more efficacious than placebo (moderate‐certainty to low‐certainty evidence). Nonsteroidal anti‐inflammatory drugs including aspirin, piroxicam, diclofenac, ketorolac, and the antidepressant medicine imipramine, may be at least as efficacious as opioids for moderate‐to‐severe background cancer pain. For breakthrough cancer pain, oral transmucosal, buccal, sublingual, or intranasal fentanyl preparations were identified as more efficacious than placebo but were more commonly associated with toxicities, including constipation and nausea. Despite being recommended worldwide for the treatment of cancer pain, morphine was generally not superior to other opioids, nor did it have a more favorable toxicity profile. The interpretation of study results, however, was complicated by the heterogeneity in the study populations evaluated. Given the limited quality and quantity of research, there is a need to reappraise the clinical utility of opioids in people with cancer pain, particularly those who are not at the end of life, and to further explore the effects of opioids on immune system function and quality of life in these individuals.

7 April 2008 in Medical Journal of Australia
Verified
Journal Article
Closed access
PDF file
AEAlison C Evans
Alison C Evans
HZHelen M Zorbas
Helen M Zorbas
MKMegan A Keaney
Megan A Keaney
MSMark A Sidhom
Mark A Sidhom
HGHolly E Goodwin
Holly E Goodwin
JPJanice C Peterson
Janice C Peterson
Concerns about medicolegal implications of a multidisciplinary approach to cancer care may act as a barrier to the implementation of best practice approaches. While multidisciplinary meetings carry ...

11 August 2024 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NANiccolo Allievi
Niccolo Allievi
MSMark Sidhom
Mark Sidhom
MSMark Vasanth Samuel
Mark Vasanth Samuel
ATAlexios Tzivanakis
Alexios Tzivanakis
SDSanjeev Dayal
Sanjeev Dayal
BMBrendan James Moran
Brendan James Moran